Insulet Corporation
Edit

Insulet Corporation

https://www.myomnipod.com/about.php
Last activity: 02.02.2016
Active - Reference to Omnipod
Categories: BrandDeliveryDrugPublicTechnology
Insulet is a publicly traded drug delivery company with a novel insulin pump technology marketed under the OmniPod brand.
Insulet is a publicly traded drug delivery company with a novel insulin pump technology marketed under the OmniPod brand.
Insulet went public in 2007.
Insulet went public in 2007.
Website visits
19K /mo.
Mentions
6
Location: United States, Massachusetts, Bedford
Employees: 1001-5000
Founded date: 2000

Investors 2

Mentions in press and media 6

DateTitleDescription
02.02.2016Insulet to Divest Neighborhood Diabetes Supplies BusinessBILLERICA, Mass. – February 2, 2016 – Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced it has entered i...
13.06.2014Joslin executive director: Mobile health apps are the future“We see that the future is with mobile apps. They will boost efficient reporting and make physicians more efficient.” Still, these tools pose their own sets of challenges. “There are a number of mobile apps that can use our expertise. There...
05.03.2013Diabetes: Insulet gains on strong Q4, lands FDA winMedical device maker Insulet (NSDQ:PODD) got a boost from Wall Street last week after releasing its 4th quarter and full-year 2012 financial report. The news sent PODD shares up 5.5% in a single day on Feb. 28 after the company hosted its e...
22.01.2010Breath-based glucose sensor developed (and why it may never make it to market)I guess since I’m the resident diabetic at CrunchGear that I should write all the diabetes-related stories. Good old diabetic Doug. He’s got the sweet blood, let’s pass this one on to him. Hope he doesn’t go into diabetic retardation while ...
16.05.2007Insulet, insulin-management device maker, raises $116M in IPOInsulet, a Bedford, Mass, developer of continuous insulin-infusion devices for diabetics, sold 7.7 million shares in an IPO, raising approximately $115 million before fees. The offering was priced at $15 per share, in the middle of Insulet’...
-Joslin executive director: Mobile health apps are the futureThis week Joslin Center for Diabetes added an Institute for Technology Translation to make it easier to work with medical device companies. In an interview with MedCity News, the executive director of the institute, Harry Mitchell, talked a...

Reviews 0

Sign up to leave a review

Sign up Log In